Clinical Trials Logo

Clinical Trial Summary

The investigators hypothesize that long-term disease-free survival (DFS) in patients with JMML can be achieved with a treatment of busulfan (BU), cyclophosphamide (CY) and melphalan (L-PAM) followed by hematopoietic cell transplantation (HCT).


Clinical Trial Description

Prior to transplantation, subjects will receive BUSULFAN via the central venous line, six times a day for four days, CYCLOPHOSPHAMIDE via the central venous line once a day for two days, and MELPHALAN via the central venous line for one day. Busulfan, cyclophosphamide, and melphalan are given to destroy the subject's leukemia. As well, these drugs will destroy the subject's own immune system to help ensure the new bone marrow takes and grows after transplantation. On the day of transplantation, bone marrow or umbilical cord blood from the donor will arrive to the bone marrow transplant unit and be transfused via venous line. These new cells will replace the subject's bone marrow. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00167219
Study type Interventional
Source Masonic Cancer Center, University of Minnesota
Contact
Status Completed
Phase Phase 1/Phase 2
Start date November 18, 1999
Completion date August 9, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03190915 - Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Phase 2
Completed NCT01093586 - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Completed NCT00078858 - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Phase 1/Phase 2
Completed NCT01020539 - Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia Phase 1
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Active, not recruiting NCT01036009 - A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies Phase 2
Completed NCT00898079 - Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Completed NCT00112593 - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer N/A
Completed NCT01445080 - Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia Phase 1/Phase 2
Completed NCT04082286 - Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia Phase 1
Terminated NCT00669890 - Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML Phase 1
Completed NCT00152139 - Stem Cell Transplantation for Patients With Hematologic Malignancies Phase 3
Completed NCT00006251 - Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Phase 1/Phase 2
Recruiting NCT05735717 - MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies Phase 2
Recruiting NCT03843528 - Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation Phase 1
Recruiting NCT03314974 - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Phase 2
Active, not recruiting NCT02338479 - Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Completed NCT01305200 - Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Phase 3
Completed NCT00697671 - Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies Phase 1
Active, not recruiting NCT00118352 - Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Phase 2